Elevidys

Indications for Use

Elevidys is used for the treatment of Duchenne muscular dystrophy (DMD) in patients who are at least 4 years of age. It is approved for use in both ambulatory patients (those who are able to walk) and non-ambulatory patients (those who are unable to walk).

This treatment is specifically for individuals who have a confirmed mutation in the DMD gene. However, it is not suitable for all patients with this condition. It is not recommended for individuals with certain specific genetic deletions, such as those in exon 8 and/or exon 9 of the DMD gene, due to potential safety concerns.

Typical Use Cases

Duchenne muscular dystrophy is a rare genetic disorder that causes progressive muscle weakness and degeneration. It primarily affects males and is caused by a lack of a protein called dystrophin, which helps keep muscle cells intact. Elevidys is administered to help the body produce a functional, shortened version of the dystrophin protein to help manage the progression of the disease.

Before receiving this therapy, patients typically undergo genetic testing to confirm the specific type of mutation they have and to ensure they do not have the specific deletions that would make the treatment unsafe for them.

Mechanism of Action

Duchenne muscular dystrophy (DMD) is caused by a genetic mutation that prevents the body from making dystrophin. Dystrophin is a vital protein that acts like a shock absorber for muscle fibers, protecting them from injury when muscles contract and relax. Without enough dystrophin, muscle cells become fragile and break down over time.

Elevidys works by addressing the underlying genetic cause of the disease. It is a one-time gene therapy that uses a viral vector to deliver a specially designed gene into the patient's muscle tissue. This process involves several steps:

• Delivery: A modified, non-harmful virus (adeno-associated virus) carries a functional gene into the muscle cells.
• Protein Production: Once the gene is inside the cells, it provides instructions for the body to produce a shortened version of the dystrophin protein, known as Elevidys micro-dystrophin.
• Muscle Protection: This micro-dystrophin protein is designed to perform some of the essential functions of the missing natural protein, helping to stabilize and protect muscle fibers from breaking down.

While the micro-dystrophin produced by Elevidys is smaller than the protein found in people without DMD, it contains the critical components needed to support muscle cell integrity.

Common Side Effects

The most frequently reported side effects of Elevidys include:

• Vomiting
• Nausea
• Fever
• Low platelet counts (thrombocytopenia)

Serious Side Effects

Some patients may experience severe reactions that require immediate medical attention. These include:

• Liver Injury: This can include elevated liver enzymes or acute liver failure. Signs may include yellowing of the skin or eyes (jaundice), dark urine, or pain in the upper right abdomen.
• Immune-mediated Myositis: This is an inflammation of the muscles that can cause muscle weakness or pain.
• Myocarditis: This is an inflammation of the heart muscle. Symptoms may include chest pain, shortness of breath, or an irregular heartbeat.

Healthcare providers will monitor patients closely before and after the infusion using blood tests to check liver function, platelet levels, and heart enzymes (troponin-I).

Acute Liver Injury

Treatment can cause acute liver injury. Healthcare providers monitor liver enzyme levels and bilirubin before the infusion and weekly for at least three months afterward. A corticosteroid regimen is required to help manage this risk.

Immune-mediated Myositis

Some patients have experienced severe muscle inflammation (myositis) following treatment. This condition can cause muscle weakness and may affect the muscles used for breathing. This risk appears higher in patients with specific genetic mutations in the DMD gene. Patients who experience new or worsening muscle weakness or pain should seek medical attention immediately.

Myocarditis

Inflammation of the heart muscle (myocarditis) has been observed after infusion. Monitoring of troponin-I levels is required before treatment and weekly for the first month to check for signs of heart injury. New symptoms like chest pain or shortness of breath require urgent evaluation.

Infusion-related Reactions

Infusion-related reactions, including hypersensitivity and anaphylaxis, can occur. Healthcare providers monitor patients during and after the administration for signs of an allergic reaction.

Vaccinations

Patients should be up to date on vaccinations before starting the corticosteroid regimen. Live vaccines should be avoided for at least four weeks before and six months after the infusion.

Pregnancy

Elevidys is indicated for the treatment of Duchenne muscular dystrophy, a genetic condition that primarily affects males. Because of this, the medication is not intended for use in women.

There are no clinical studies or data regarding the use of Elevidys in pregnant individuals. It is unknown if the medication could cause harm to a developing fetus. Additionally, animal reproduction studies have not been conducted to evaluate the potential risks of this gene therapy during pregnancy.

Breastfeeding

There is no information available concerning the presence of Elevidys in human breast milk. It is also unknown how the medication might affect a breastfed infant or the production of milk. Individuals with questions about gene therapy and its potential impacts should consult their healthcare provider.

Dosage Forms

Elevidys is a sterile, preservative-free suspension intended for intravenous infusion. It is supplied in a kit containing multiple vials.

Packaging

The medication is provided in kits tailored to the patient's weight. Each kit contains the required number of vials for the treatment.

FDA Approval History

Elevidys (delandistrogene moxeparvovec-rokl) first received accelerated approval from the U.S. Food and Drug Administration (FDA) in June 2023. This initial approval was limited to ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) and a confirmed mutation in the DMD gene.

In June 2024, the FDA expanded the approval to include a broader population. The current regulatory status includes:

• Traditional Approval: Granted for the treatment of ambulatory patients aged 4 years and older with DMD and a confirmed mutation in the DMD gene.
• Accelerated Approval: Granted for the treatment of non-ambulatory patients aged 4 years and older with DMD and a confirmed mutation in the DMD gene. Continued approval for this specific group may be contingent upon verification of clinical benefit in confirmatory trials.

Regulatory Considerations

The FDA has identified certain limitations and safety considerations for the use of Elevidys:

• Contraindications: The therapy is not approved for patients with any deletion in exon 8 and/or exon 9 of the DMD gene due to safety risks.
• Post-Marketing Requirements: As part of the accelerated approval process, the manufacturer is required to conduct further clinical studies to confirm the drug's clinical benefit in non-ambulatory patients.

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required for this medication.

Cost Considerations

Elevidys is a specialized gene therapy administered as a single intravenous infusion. Because it is a one-time treatment rather than a recurring medication, the cost structure differs from traditional drugs taken daily or monthly.

Insurance and Out-of-Pocket Costs

The amount a patient pays for Elevidys will vary based on their specific health insurance plan. Factors that influence the final cost include:

• Insurance provider and specific plan benefits.
• Deductibles and out-of-pocket maximums.
• Prior authorization requirements from the insurance company.

Financial Assistance

Support programs may be available to help families manage the costs associated with this treatment. These programs often provide assistance with navigating insurance claims or offer financial aid to those who qualify based on medical and financial criteria.

Additional Expenses

Beyond the cost of the drug itself, patients may incur expenses related to the administration process, including:

• Specialized medical facility fees for the infusion.
• Required laboratory tests and monitoring before and after the procedure.
• Travel and lodging if the treatment is performed at a specialized center far from home.